Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double blind, double-dummy, placebo controlled trial of inhaled treatment to establish the mechanisms of prematurity-associated airway obstruction and inflammation

Next Previous
Trial Profile

A randomised, double blind, double-dummy, placebo controlled trial of inhaled treatment to establish the mechanisms of prematurity-associated airway obstruction and inflammation

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone propionate (Primary) ; Salmeterol
  • Indications Obstructive airway disorders
  • Focus Therapeutic Use
  • Acronyms RHINO

Most Recent Events

  • 13 Dec 2021 Primary endpoint (the difference in pre-and post-treatment percent predicted Forced Expiratory Volume in 1 second (FEV1) after 12 weeks of therapy between the treatment groups) has been met according to the results published in the JAMA Pediatrics
  • 13 Dec 2021 Results published in the JAMA Pediatrics
  • 18 Nov 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top